Trial Profile

A phase III multicentre, randomized, double-blind and active-controlled clinical assessing efficacy of Fexuprazan, vs. Esomeprazole in Chinese Patients with Erosive Esophagitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2023 According to a Daewoong Pharmaceuticals, company has submitted the New Drug Application (NDA) for Fexuprazan to the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA), based on the results of Phase 3 clinical trials for GERD treatment conducted on 332 patients with erosive esophagitis in China.
21 Jun 2023 New trial record
09 May 2023 Status changed from recruiting to completed according to results presented at the Digestive Disease Week 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com